Forte Biosciences Files 8-K on Security Holder Rights
Ticker: FBRX · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1419041
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Forte Biosciences filed an 8-K, expect changes to security holder rights.
AI Summary
On August 27, 2024, Forte Biosciences, Inc. filed an 8-K report detailing material modifications to the rights of security holders and other events. The filing indicates changes related to the company's charter or bylaws and includes financial statements and exhibits. The company, formerly known as Tocagen Inc., is incorporated in Delaware and based in Dallas, Texas.
Why It Matters
This 8-K filing signals potential changes in the rights of Forte Biosciences' security holders, which could impact their investment value and voting power.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights can introduce uncertainty and potential shifts in corporate control or value.
Key Numbers
- 001-38052 — SEC File Number (Identifies the company's filing with the SEC)
- 26-1243872 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Forte Biosciences, Inc. (company) — Registrant
- Tocagen Inc. (company) — Former company name
- August 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Dallas, Texas (location) — Principal executive offices
FAQ
What specific modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item, but the specific details of these modifications are not elaborated in the provided text.
What are the key items reported in this 8-K filing?
The key items reported are Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 27, 2024.
What is the former name of Forte Biosciences, Inc.?
The former name of Forte Biosciences, Inc. was Tocagen Inc., with a date of name change on November 20, 2007.
Where are Forte Biosciences, Inc.'s principal executive offices located?
Forte Biosciences, Inc.'s principal executive offices are located at 3060 Pegasus Park Drive, Building 6, Dallas, Texas, 75247.
Filing Stats: 1,076 words · 4 min read · ~4 pages · Grade level 11.3 · Accepted 2024-08-30 16:06:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value FBRX The NASDAQ Stock Mar
Filing Documents
- d838050d8k.htm (8-K) — 31KB
- d838050dex31.htm (EX-3.1) — 8KB
- 0001193125-24-211066.txt ( ) — 166KB
- fbrx-20240827.xsd (EX-101.SCH) — 3KB
- fbrx-20240827_lab.xml (EX-101.LAB) — 18KB
- fbrx-20240827_pre.xml (EX-101.PRE) — 11KB
- d838050d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Forte Biosciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FORTE BIOSCIENCES, INC. Date: August 30, 2024 By: /s/ Antony Riley Antony Riley Chief Financial Officer